CJC-1295 between the hormone pulses

Two CJC-1295 forms

The name CJC-1295 often covers two different durations. The long-acting form carries DAC, short for drug affinity complex: an attachment that binds it to albumin in blood. Modified GRF (1-29), often called no-DAC, lacks that attachment and is short-acting. The review of growth hormone-releasing hormone analogues gives the pharmacological background.

CJC-1295 stimulates the pituitary gland to release growth hormone, which in turn raises IGF-1, a growth factor made largely in the liver. Albumin binding prolongs the message. I’m particular about the form here because the human results that made CJC-1295 famous concern the long-acting design. They cannot simply be transferred to the short-acting material.

CJC-1295 hormone results

The clearest duration figures come from an early study in healthy adults. After a single administration, mean growth hormone rose 2- to 10-fold for 6 days or more. IGF-1 rose 1.5- to 3-fold for 9–11 days. After multiple administrations, IGF-1 remained above baseline for up to 28 days. The estimated CJC-1295 half-life was 5.8–8.1 days.

Half-life describes how quickly the amount of a substance falls; the hormone response is a separate measurement. Those are already two clocks to follow. Neither tells me whether sleep, healing or physical function improved. The paper established a prolonged biological response, and the broader clinical questions remained open.

Baseline and pulses

Growth hormone normally arrives in bursts. Repeated sampling in healthy men found approximately a 7.5-fold rise in the trough, the level between bursts. Mean growth hormone was about 46% higher and IGF-1 about 45% higher one week later. Pulse frequency and magnitude showed no clear change.

The trough is the intriguing part for me. A description such as “pulses preserved” sounds reassuring until the much higher background comes into focus. The rhythm persisted alongside greater exposure. I’m waiting for health outcomes and long-term harm data before calling that pattern desirable.

Serum proteins

A study of 11 healthy young men examined changes in the serum protein profile. An albumin fragment and an immunoglobulin-related signal rose with IGF-1. Serum is the fluid left after blood clots; it carries many proteins beyond the hormone being sought.

This is a pleasingly untidy addition to the story. CJC-1295 altered more than the headline hormone values, and the extra signals were candidates for further investigation. They had not been validated as measures of better health. I’m leaving the serum-protein question open until those changes reproduce.

Sleep accounts

Community accounts describe deeper sleep, recovery, gradual body changes, puffiness and tingling hands. These are anecdotal accounts, not clinical evidence. They offer neither a reliable rate of effects nor a way to separate the peptide from changes in training, food, sleep or other substances.

CJC-1295 has no approved human use. Its brief, small human studies leave long-term safety unsettled. The growth-hormone-secretagogue safety review identifies reduced insulin sensitivity and higher blood glucose as class concerns and calls for longer evidence on cancer and mortality. Fluid retention and nerve-compression symptoms are also concerns with excessive growth-hormone activity. CJC-1295 is prohibited in tested sport.

The long duration sharpens those questions for me. A signal that lasts for days also prolongs the exposure being evaluated. The combination with ipamorelin adds another uncertainty: evidence about CJC-1295 alone cannot establish the effects of the pair.